Mibefradil (dihydrochloride)

• UNSPSC Description:

  Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels (IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively)[1].

• Target Antigen:

  Calcium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Mibefradil-dihydrochloride.html

• Solubility:

  H2O : 150 mg/mL (ultrasonic)

• Smiles:

  O=C(O[C@@]1(CCN(CCCC2=NC3=CC=CC=C3N2)C)[C@@H](C(C)C)C4=C(C=C(F)C=C4)CC1)COC.[H]Cl.[H]Cl

• Molecular Weight:

  568.55

• References & Citations:

  [1]Mehrke G, et al. The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1483-8.|[2]Brain KL, et al. The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens. J Physiol. 2003 Dec 1;553(Pt 2):627-35.|[3]Yu YF, et al. Protection of the cochlear hair cells in adult C57BL/6J mice by T-type calcium channel blockers. Exp Ther Med. 2016 Mar;11(3):1039-1044.|[4]Shiue SJ, et al. Chronic intrathecal infusion of T-type calcium channel blockers attenuates CaV3.2 upregulation in nerve-ligated rats. Acta Anaesthesiol Taiwan. 2016 Oct 17. pii: S1875-4597(16)30071-6.ACS Nano. 2024 Oct 31.|Front Pharmacol. 2022 Feb 23;13:816133.|PLoS Biol. 2024 Mar 25;22(3):e3002565.|Res Sq. 2024 Jun 11.|Small. 2024 Aug 10:e2403381.|Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868.|Br J Pharmacol. 2021 Jan;178(2):346-362.|Eur J Pharmacol. 2021 Feb 5;892:173782.|Front Pharmacol. 23 February 2022.|J Cell Physiol. 2021 Mar 11.|Mediat Inflamm. 2020 Nov 10;2020:3691701.|Theriogenology. 2021 Jan 1;159:140-146.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  116666-63-8